Shares of TransMedics Group, Inc. (TMDX) surged 9.33% in after-hours trading on Thursday following the release of its impressive first-quarter 2025 financial results. The medical technology company, which focuses on organ transplant solutions, significantly outperformed analysts' expectations across multiple financial metrics.

TransMedics reported quarterly earnings of $0.70 per share, demolishing the analyst consensus estimate of $0.25 by a staggering 180%. This represents a 100% increase from the same period last year when the company earned $0.35 per share. Revenue for the quarter came in at $143.54 million, beating the analyst estimate of $123.66 million by 16.07% and marking a 48.21% year-over-year increase.

The company's profitability also showed remarkable improvement. TransMedics reported an income from operations of $27.443 million, more than doubling the IBES estimate of $10.1 million. The gross profit stood at $88.228 million with a robust gross margin of 61%. Additionally, the company provided an optimistic full-year revenue outlook of $565-585 million, further fueling investor enthusiasm. These strong results and positive outlook appear to be the primary drivers behind the stock's significant after-hours rally.